Abstract
Maternal Serum Screening For Prenatal Diagnosis of Some Fetal Genetic Disorders Based on elevated MSAFP levels, 85% to 90% of NTDs can be detected. Using a combination of the three parameters, MSAFP, hCG and UE3, 55% to 60% of fetal Down's syndrome can be detected. Future strategies for Down's syndrome screening may include the use of new markers such as dimeric inhibin-A and urinary /5-core fragment of hCG, as well as first-trimester screening, particularly with PAPP-A and free /3-hCG.
MSAFP düzeylerindeki arüşa bağlı olarak NTD'lerinin %85-90'ı tespit edilebilir. MSAFP, hCG ve uE3 serum parametreleri kombine edildiğinde de fetal Down sendromlannın %55-60'ı tespit edilebilir. Down sendrom taramasında gelecekte kullanılabilecek yeni markırlar dimeric inhibin-A ve hCG'nin idrar p-core fragment'ı ve ilk trimestrda özellikle free fi-hCG ve PAPP-A'dır.
Keywords
Details
| Primary Language | English |
|---|---|
| Authors | |
| Submission Date | December 21, 2009 |
| Publication Date | December 23, 2009 |
| DOI | https://doi.org/10.5835/jecm.v16i1.802 |
| IZ | https://izlik.org/JA42BL76DZ |
| Published in Issue | Year 1999 Volume: 16 Issue: 1 |
Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.